Dediabetes Logo
Centro de evidencia
Descubre que funciona
Evidence Explorer
Busca en el grafo completo de evidencia
Investigacion reciente
Estudios mas recientes
Que cambio
Inteligencia semanal
Configuracion
Entrar / Unirse
Resumen de Investigación
Analyzed using Evidence Intelligence™

Tirzepatide shows greater HbA1c and weight reduction than Semaglutide

Desarrollado con el marco Evidence Intelligence™ de Dediabetes

Última actualización 4 de julio de 2026

Key finding

In Hispanic or Latino patients, the LSM change from baseline in HbA1c at 40 weeks was -2.11% with Tirzepatide 5 mg (p<0.001).

This study compared the effects of Tirzepatide and Semaglutide on HbA1c and body weight in Hispanic or Latino patients with Type 2 Diabetes, finding significant reductions with Tirzepatide.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Medium-Term (3–12 mo)

Risk of bias

Some Concerns

Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

This study compared the effects of Tirzepatide and Semaglutide on HbA1c and body weight in Hispanic or Latino patients with Type 2 Diabetes, finding significant reductions with Tirzepatide.

Clinical relevance

These findings are clinically significant as they suggest that Tirzepatide may offer superior glycemic control and weight management for Hispanic or Latino patients with Type 2 Diabetes. This could lead to improved health outcomes and quality of life for patients in this demographic, who may respond differently to diabetes treatments.

Keep in mind

The study focused only on Hispanic or Latino patients, limiting generalizability. Results may not apply to patients with other ethnic backgrounds. Long-term effects beyond 40 weeks were not assessed.

Published in

Referencia de la Revista

Publication details and source links for this paper.

Brian DB, Katelyn B, Raleigh EM, Hui W, Juan PF. Tirzepatide versus Semaglutide in Hispanic or Latino Patients with Type 2 Diabetes: A Subgroup Analysis of SURPASS-2. Journal of the Endocrine Society. 2022;6(Suppl 1):A355-A356. doi:10.1210/jendso/bvac150.738

View DOIView on PMC

Efectos Principales

Tirzepatide 5 mg reduced HbA1c by -2.11% (p<0.001).

Tirzepatide 10 mg reduced HbA1c by -2.46% (p<0.001).

Tirzepatide 15 mg reduced HbA1c by -2.47% (p<0.001).

Semaglutide reduced HbA1c by -1.93% (p<0.001).

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Semaglutide, Tirzepatide and Body weight, HbA1c, Weight change.

This study contributes evidence to

Intervention

Semaglutide

Outcome

Body weight

Evidence topic

Weight Loss

Primary intervention

Semaglutide

Primary outcomes

  • Body weight
  • HbA1c
  • Weight change

Evidence topics

Weight LossHbA1c ReductionGLP-1 Receptor Agonists

Primary intervention

Semaglutide

Primary outcomes

Body weightHbA1cWeight change

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

5
Evidence pairs
5
Relationships
3
Evidence topics
contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 68

3

Related topics

5

Evidence pairs

546

Related studies

High relevance in at least one topic

Why it is useful

  • Contributes to 5 evidence relationships
  • Includes primary outcome data
  • Linked to 3 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Agrega evidencia relacionada a tu Evidence Tracker

Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.

Evidencia principal

Relación de evidencia

GLP-1 Receptor Agonists and HbA1c

Evidencia relacionada

Relación de evidencia

GLP-1 Receptor Agonists and Body Weight

Guardar evidencia

Tema de evidencia

Weight Loss

Guardar evidencia

Core evidence

Study findings

The primary outcomes reported in this study.

Body weight

Semaglutide → Body weight

Semaglutide → Body weight

Evidence Intelligence™
EvidenceScore™
87
Strong
ImpactScore™
72
Positive
ConsistencyScore™
88
consistent
Estudios de apoyo: Basado en 9 estudios
Add to Evidence Tracker

HbA1c

Semaglutide → HbA1c

Semaglutide → HbA1c

Evidence Intelligence™
EvidenceScore™
87
Strong
ImpactScore™
91
Very Positive
ConsistencyScore™
82
consistent
Estudios de apoyo: Basado en 11 estudios
Add to Evidence Tracker

Body weight

Tirzepatide → Body weight

Tirzepatide → Body weight

Evidence Intelligence™
EvidenceScore™
83
Strong
ImpactScore™
95
Very Positive
ConsistencyScore™
100
consistent
Estudios de apoyo: Basado en 11 estudios
Add to Evidence Tracker

HbA1c

Tirzepatide → HbA1c

Tirzepatide → HbA1c

Evidence Intelligence™
EvidenceScore™
84
Strong
ImpactScore™
96
Very Positive
ConsistencyScore™
100
consistent
Estudios de apoyo: Basado en 12 estudios
Add to Evidence Tracker

Weight change

Tirzepatide → Weight change

Tirzepatide → Weight change

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

evidence suggest

La Evidencia Sugiere

  • Tirzepatide 10 mg led to a body weight reduction of -9.7 kg (p<0.001).
  • Tirzepatide 15 mg resulted in a body weight reduction of -10.5 kg (p<0.001).
  • Semaglutide resulted in a body weight reduction of -5.6 kg (p<0.001).
who this applies

A quién se aplica

  • Hispanic or Latino adults with Type 2 Diabetes.
  • Patients seeking effective glycemic control and weight management.
keep in mind

Tener en Cuenta

  • The study's findings are specific to Hispanic or Latino patients.
  • Further research is needed to confirm long-term effects.
  • Individual responses to treatment may vary.
between the lines

Entre Líneas

  • The study focused only on Hispanic or Latino patients, limiting generalizability.
  • Results may not apply to patients with other ethnic backgrounds.
  • Long-term effects beyond 40 weeks were not assessed.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

Desarrollado con el marco Evidence Intelligence™ de Dediabetes

This study contributes to evidence on GLP-1 Receptor Agonists and Body Weight, GLP-1 Receptor Agonists and HbA1c.

Relaciones de evidencia relacionadas

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Does GLP-1 Receptor Agonists improve HbA1c?

Strong Evidence

GLP-1 Receptor Agonists appears to improve HbA1c.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    HbA1c

    EvidenceScore™ Strong | EvidenceScore™ 86.5 | strong positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 29 supporting studies with consistent results and a positive effect signal.

Limitations

  • Population details are unavailable.
29 supporting studiesUpdated: Jul 2026
View Full Evidence

Does GLP-1 Receptor Agonists affect body weight?

Strong Evidence

GLP-1 Receptor Agonists appears to improve Body Weight.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    Body weight

    EvidenceScore™ Strong | EvidenceScore™ 86.7 | moderate positive | ConsistencyScore™ Consistent | 1 study

  2. 2

    Weight change

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on 30 supporting studies with consistent results and a positive effect signal.

Limitations

  • Population details are unavailable.
30 supporting studiesUpdated: Jul 2026
View Full Evidence
Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

Weight Loss Evidence HubHbA1c Reduction Evidence HubGLP-1 Receptor Agonists Evidence Hub

Explore in Evidence Explorer

Open broader Evidence Explorer views for this relationship.

All studies on Semaglutide and Body weightAll studies on Semaglutide and HbA1cAll studies on Tirzepatide and HbA1cAll studies on Tirzepatide and Body weight

Related research

Read related research summaries.

Semaglutide may reduce cardiovascular events in non-diabetic patients.Oral semaglutide reduces cardiovascular events in type 2 diabetesTirzepatide improves glycemic control in early-onset type 2 diabetesHigher semaglutide doses improve glucose control in type 2 diabetesNovel Semaglutide Injection Shows Non-Inferior Glycemic Control

Sin anuncios. Sin rastreo.

Centrada en la evidencia, no en la publicidad.

Segura y privada

Tus datos siempre están protegidos.

Siempre al día

Se agregan nuevos estudios todos los días.